KPV
Calms inflammation in the gut and skin. A tripeptide fragment of alpha-MSH used for gut conditions and skin inflammation.
KPV: Calms inflammation in the gut and skin. A tripeptide fragment of alpha-MSH used for gut conditions and skin inflammation. KPV is a tiny anti-inflammatory peptide.
KPV is a tiny anti-inflammatory peptide. Used for gut conditions like IBD and inflammatory skin issues. Pairs naturally with BPC-157 for gut protocols.
Small fragment of naturally occurring alpha-MSH, but supplementing exogenously generally disqualifies strict natty claims.
Recommended by FDA's advisory committee on July 23, 2026, against the recommendation of FDA's review staff. The vote is advisory, does not bind FDA, and no rulemaking has followed.
Not prescribed in conventional medicine.
Who it's for
- →Users with IBD-spectrum or chronic gut inflammation
- →People with inflammatory skin conditions
- →Healing stacks where inflammation is the limiter
What to expect
- Week 1
GI users often notice symptom relief within days.
- Week 4
Cumulative anti-inflammatory effect.
- Week 8
Plateau. Cycle off, reassess baseline.
Looking at KPV? Your next 3 steps
- 1Work out your syringe units
Vial size + BAC water turns into the exact units to draw for KPV.
Open calculator → - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide → - 3Save it & ask the Coach
A free account gets you Coach questions every day, free; membership saves your stack and makes the Coach stack-aware.
Create free account →
How it works (mechanism)
Tripeptide fragment of alpha-MSH (lysine-proline-valine) that retains the anti-inflammatory melanocortin signal but loses the pigmentation effect. Inhibits NF-κB and downregulates pro-inflammatory cytokines locally.
Dosing protocol
Stacks well with
Side effects
When NOT to use
- ⚠Pregnancy / nursing, no data
Common mistakes
- • Skipping BPC-157 in a gut protocol, they work together, not as substitutes
- • Underdosing for stubborn inflammation
- • Expecting fast results on chronic conditions
What it actually is
KPV is three amino acids — lysine, proline, valine — the tail end of alpha-MSH, the same hormone family behind the tanning peptides. That tiny fragment carries anti-inflammatory activity without the pigmentation or appetite effects of the full hormone. It is used for gut and skin inflammation. It has no human trials, and this page previously said otherwise for a reason worth knowing about.
Alpha-MSH suppresses inflammation partly through NF-kB, a master switch that turns on inflammatory gene programmes. KPV appears to retain that action while being too small to activate the melanocortin receptors responsible for tanning and appetite. The argument for taking it orally is that a tripeptide might survive conditions that destroy larger peptides and reach the intestine intact. That is a plausible rationale rather than a demonstrated one — no human absorption study supports it.
Forms, and which is which
The most common route, on the argument that a tripeptide can reach the intestine intact and act locally.
Verdict: The most mechanistically sensible route for a gut goal.
Compounded at low percentages for inflammatory skin conditions. Systemic absorption has not been characterised, so 'local only' is an assumption rather than a measurement.
Verdict: Probably the lowest-exposure route, on unmeasured pharmacokinetics.
Used for systemic anti-inflammatory effect. Given the very short peptide and unclear pharmacokinetics, what systemic exposure actually results is not characterised.
Verdict: The most speculative route.
The common gut stack. Combines two compounds with no human efficacy evidence.
Verdict: Two unknowns, no attribution.
What it is claimed to do, graded
No human trials. The supporting work is cell culture and animal models of colitis. Zero randomised and zero human trial records are indexed.
A 2025 study shows protection of keratinocytes against particulate-induced damage in culture. Cell-culture evidence.
Reasonably well supported mechanistically in model systems.
A 2026 paper reports this in a model system. Model-system evidence, and new.
Worth stating explicitly. An earlier version of this catalog graded KPV on trials that were about IVF, newborn erythropoietin and liver metastases — papers matched because a three-letter name searches investigator lists and unrelated abbreviations, not the compound. The real count is zero.
Grades describe how much human evidence exists for that specific claim, not whether it will work for you or whether it is safe.
Pros and cons
- • No serious harms reported in anecdotal use — though FDA's 2026 review found no clinical studies and no adequate human exposure data by any route, so this is absence of reports rather than a safety finding
- • Small enough to plausibly survive digestion, which makes the oral route mechanistically reasonable
- • No pigmentation or appetite effects, unlike the rest of the alpha-MSH family
- • Topical use plausibly limits systemic exposure, though nobody has measured it
- • Cheap
- • Zero human trials of any kind
- • Its evidence grade was previously inflated by a search artefact rather than by data, which is a caution about anything you read about it elsewhere
- • Pharmacokinetics are poorly characterised, so systemic dosing is guesswork
- • Research-chemical supply with unverified identity
- • Frequently sold as an established gut treatment
When to stop
- • Symptoms worsening rather than improving over a full course
- • Any new infection that is slow to clear
- • Skin irritation where applied topically
- • Any new cancer diagnosis
Interactions
Additive immune dampening is plausible and unstudied.
Same hormone family, though KPV lacks the receptor activity that drives their effects.
The usual gut pairing. Makes any effect unattributable.
Suppressing inflammatory signalling in a body with a tumour is unstudied.
There is no human interaction literature for this compound.
Is this for you?
- • People trying the topical or oral route for a specific inflammatory problem, understanding there is no human evidence
- • You want something with human trial support
- • You are on immunosuppressants
- • You have active cancer
- • You are pregnant or nursing
The one number
Sources for the claims above
- Mitigates fine dust-induced keratinocyte apoptosis and inflammation
- Attenuates hepatic lipid accumulation in a model system
- Oral peptide delivery via inflammation-triggered conjugates
Drug & supplement interactions
- ⚠Limited documented interactions
- ⚠BPC-157 paired commonly for gut protocols
Community patterns
New to KPV? Grab the starter checklist.
Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.
Numbers redacted in this preview. Members get the full answer, on their own stack.
Ask the Coach anything about KPV or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Unlock the full Coach, from $4.99/week →Frequently asked
What is KPV?+
Is KPV FDA approved?+
Is KPV legal?+
Is KPV banned by WADA?+
Are you still natty after taking KPV?+
Do doctors prescribe KPV?+
What's the typical dose of KPV?+
What are the side effects of KPV?+
How long until KPV starts working?+
What can you stack with KPV?+
Where do people get KPV?+
Common questions about KPV
Tracked alongside KPV
Same goal, different aisle — each graded on its own evidence in the Pepdex catalog.
More in Immune
Immune-system peptide. Approved in many countries for hepatitis B/C and as adjunct to chemotherapy. Used here for chronic immune issues and post-illness recovery.
A germ-fighter your immune system already makes on its own. It's a cathelicidin-derived antimicrobial peptide used for chronic infections and biofilm-associated issues.
Endogenous 28-amino-acid neuropeptide. Modulates immune function and inflammation. Used in CIRS (chronic inflammatory response syndrome) protocols and biotoxin exposure recovery, popularized by Dr. Ritchie Shoemaker.
Used to rebuild a weakened immune system, mainly in older or post-illness patients. A polypeptide complex extracted from calf thymus and distinct from Thymosin Alpha-1, used in Russian and Eastern European clinical practice for immune restoration in elderly patients and post-illness recovery.